Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit: 2010-2024

Historic Gross Profit for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$2.0 million.

  • China Pharma Holdings' Gross Profit rose 88.52% to -$59,654 in Q3 2025 from the same period last year, while for Sep 2025 it was -$443,314, marking a year-over-year increase of 76.72%. This contributed to the annual value of -$2.0 million for FY2024, which is 606.42% down from last year.
  • Per China Pharma Holdings' latest filing, its Gross Profit stood at -$2.0 million for FY2024, which was down 606.42% from -$281,085 recorded in FY2023.
  • China Pharma Holdings' Gross Profit's 5-year high stood at $2.0 million during FY2020, with a 5-year trough of -$2.0 million in FY2024.
  • Moreover, its 3-year median value for Gross Profit was -$493,916 (2022), whereas its average is -$920,216.
  • As far as peak fluctuations go, China Pharma Holdings' Gross Profit surged by 43.09% in 2023, and later slumped by 606.42% in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' Gross Profit stood at $2.0 million in 2020, then tumbled by 82.12% to $349,270 in 2021, then plummeted by 241.41% to -$493,916 in 2022, then skyrocketed by 43.09% to -$281,085 in 2023, then plummeted by 606.42% to -$2.0 million in 2024.